Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Roundup: Abstract Data Presented at ACR Convergence 2021

Keri Losavio  |  Issue: May 2022  |  February 11, 2022

Conclusion: In this phase 2 study, tigulixostat significantly lowered sUA levels in gout patients with hyperuricemia compared to placebo at all dose levels (P<0.0001), and sUA lowering effect of tigulixostat appeared to be dose dependent. Treatment with tigulixostat at all three dose levels appeared to be well tolerated by study participants.

Patient Perspective

Abstract 0668: Patient perspectives and preferences regarding gout and gout management: impact on adherence3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Chung MK, et al.

Patient-centered management is becoming increasingly important in gout, but few studies have explored patients’ perspectives and preferences. Chung et al. investigated patients’ perspectives and preferences regarding gout and gout management, and their impacts on adherence to urate-lowering therapy (ULT).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Methods: A paper-based survey was conducted among patients with gout seen at the rheumatology outpatient clinics of 16 tertiary hospitals. The survey included questions regarding demographics, comorbidities, gout attacks, current treatment and adherence, and patients’ perspectives and preferences regarding gout and gout management. Multivariate regression analysis was performed to determine the factors associated with ULT adherence. Results: Of 809 surveyed patients with gout, 755 (94.5%) were using ULT. Among those using ULT, 89.1% had ≥80% adherence to ULT. The majority of the patients knew management strategies to some extent (94.8%), perceived gout as a life-long disease (91.2%) and were making efforts toward practicing at least one lifestyle modification (89.2%). Most patients (71.9%) obtained information about gout management during their clinic visits. Approximately half of the patients (53.6%) preferred managing their disease with both ULT and lifestyle modification, 28.4% preferred ULT only, and 17.4% preferred lifestyle modification only. Adherence was better in older patients, those with better knowledge of gout management strategies and those who had a preference for ULT.

Conclusion: Patients’ perspectives and management preferences had high impacts on adherence to ULT in gout. Consideration of patients’ perspectives and preferences is important for achieving the desired clinical outcome in gout.

Keri Losavio is the staff editor of The Rheumatologist.

References

Refer to the ACR meeting abstracts for full details on all of the studies summarized here: https://acrabstracts.org.

  1. Yoshida K, Liu J, Solomon D, et al. Comparative safety of gout ‘treat-totarget’ and ‘usual care’ treatment strategies on cardiovascular outcomes using observational data: causal inference approach [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  2. Terkeltaub R, Mune J, Lee J, Saag K. Phase 2 study results from a randomized, double-blind, placebo-controlled, dose-finding study to evaluate efficacy and safety of tigulixostat, a novel non-purine selective xanthine oxidase inhibitor, in gout patients with hyperuricemia [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).
  3. Chung M, Kim S, Cheon Y, et al. Patient perspectives and preferences regarding gout and gout management: impact on adherence [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting ReportsPatient PerspectiveResearch Rheum Tagged with:ACR Convergence – GoutACR Convergence 2021 – GoutGouttigulixostatTreat-to-Target

Related Articles

    Tigulixostat Appears Promising for the Treatment of Gout

    February 2, 2022

    In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.

    New Draft Gout Guideline Released

    November 20, 2019

    ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…

    Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021’

    November 10, 2021

    Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.

    Akarat Phasura / shutterstock.com

    The ACR Releases a New Gout Guideline

    June 15, 2020

    In May, the ACR released a new treatment guideline for the management of gout for simultaneous publication in Arthritis & Rheumatology and Arthritis Care & Research.1 Based on evidence from more than 130 published studies, the guideline makes a total of 42 recommendations—of which 16 are strong: It has 27 recommendations for urate-lowering therapy (ULT)…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences